- Home
- PPBT vs PSTV Comparison
PPBT vs PSTV Comparison
Compare PPBT & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- PSTV
- Stock Information
- Founded
- PPBT 2010
- PSTV 1996
- Country
- PPBT Israel
- PSTV United States
- Employees
- PPBT N/A
- PSTV N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- PPBT Health Care
- PSTV Health Care
- Exchange
- PPBT Nasdaq
- PSTV Nasdaq
- Market Cap
- PPBT 6.3M
- PSTV 10.4M
- IPO Year
- PPBT N/A
- PSTV N/A
- Fundamental
- Price
- PPBT $2.49
- PSTV $0.30
- Analyst Decision
- PPBT Strong Buy
- PSTV Strong Buy
- Analyst Count
- PPBT 1
- PSTV 3
- Target Price
- PPBT $33.00
- PSTV $10.83
- AVG Volume (30 Days)
- PPBT 22.4K
- PSTV 59.6M
- Earning Date
- PPBT 08-15-2025
- PSTV 08-13-2025
- Dividend Yield
- PPBT N/A
- PSTV N/A
- EPS Growth
- PPBT N/A
- PSTV N/A
- EPS
- PPBT N/A
- PSTV N/A
- Revenue
- PPBT N/A
- PSTV $5,206,000.00
- Revenue This Year
- PPBT N/A
- PSTV $13.26
- Revenue Next Year
- PPBT N/A
- PSTV $8.84
- P/E Ratio
- PPBT N/A
- PSTV N/A
- Revenue Growth
- PPBT N/A
- PSTV N/A
- 52 Week Low
- PPBT $2.00
- PSTV $0.16
- 52 Week High
- PPBT $13.95
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- PPBT 52.01
- PSTV 45.82
- Support Level
- PPBT $2.26
- PSTV $0.30
- Resistance Level
- PPBT $2.50
- PSTV $0.37
- Average True Range (ATR)
- PPBT 0.13
- PSTV 0.05
- MACD
- PPBT 0.00
- PSTV 0.02
- Stochastic Oscillator
- PPBT 58.82
- PSTV 50.00
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).